Advaxis Inc (ADXS) 7.18 $ADXS
Advaxis Appoints Mayo Pujols Vice President, Manufacturing
GlobeNewswire - Fri Feb 13, 9:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Mayo Pujols as Vice President, Manufacturing. Mr. Pujols brings to Advaxis more than 22 years of experience in global commercial and clinical manufacturing, technology transfer, and product development strategy.
ADXS: 7.18 (+0.06), MRK: 58.81 (-0.07)
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 12, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), CYAN: 8.72 (+0.13), STMP: 56.92 (-0.24), EPRS: 7.67 (+0.67), EEFT: 53.96 (-0.91), PRQR: 18.32 (-0.86), GTIM: 8.23 (+0.07), DPRX: 12.76 (+0.26), EXPE: 89.49 (-0.08), CVV: 14.68 (-0.26), DGLY: 11.50 (-0.40), DWSN: 6.89 (-0.42)
Advaxis teams up with Incyte in cervical cancer
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 10:47AM CST
ADXS: 7.18 (+0.06), INCY: 75.94 (+0.28)
Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer
GlobeNewswire - Wed Feb 11, 9:55AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte Corporation (Nasdaq:INCY) to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). The Phase 2 multicenter, open-label, preoperative window-study will evaluate the safety and efficacy of ADXS-HPV as a monotherapy and in combination with epacadostat in approximately 20 patients with Stage I-IIa human papillomavirus (HPV)-associated cervical cancer.
ADXS: 7.18 (+0.06), INCY: 75.94 (+0.28)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:13AM CST
FCEL: 1.31 (unch), ADXS: 7.18 (+0.06), JONE: 10.18 (+0.18), INXN: 32.04 (+0.14), SDRL: 12.32 (-0.70), NBG: 1.61 (+0.18), GNW: 8.67 (+0.17), WBAI: 17.36 (-0.30), PME: 2.42 (-0.07), RAD: 8.34 (+0.25), BLDP: 2.66 (-0.26), BXE: 2.79 (+0.05), PXD: 157.85 (+9.71), ACHN: 10.89 (-0.20), SDR: 4.66 (+0.10), LGF: 32.17 (+0.08), PIR: 12.52 (+0.17), AOL: 41.78 (+1.22), GNRC: 49.89 (+0.29), GOL: 3.85 (+0.01), DCTH: 1.14 (+0.04), CHS: 18.38 (+0.10)
Biotech Stocks Review - Arena Pharma, Amgen, NPS Pharma, ZIOPHARM Oncology, and Advaxis
PR Newswire - Fri Feb 06, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Amgen Inc. (NASDAQ: AMGN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Advaxis Inc. (NASDAQ: ADXS). Free research report on Arena Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Arena%20P...amp;s=ARNA. On Thursday, February 05, 2015, the NASDAQ Composite ended at 4,765.10, up 1.03%, the Dow Jones Industrial Average advanced 1.20%, to finish the day at 17,884.88, and the S&P 500 closed at 2,062.52, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 813.68, up 1.64%, with the index also advancing 4.56% in the last three months. Register for your complimentary reports at the links given below.
ADXS: 7.18 (+0.06), ZIOP: 9.64 (-0.35), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), ARNA: 4.55 (+0.02)
Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx
at The Street - Fri Feb 06, 5:05AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BLUE: 90.70 (+0.93), ADXS: 7.18 (+0.06), GILD: 101.90 (+1.10), HEB: 0.25 (+0.01), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
Lifshitz & Miller Law Firm Announces Investigation of Advanced Photonix, Inc., Advaxis, Inc., Advent Software, Inc., Books-A-Million, Inc., City National Corporation, Energy Recovery, Inc., and NetScout Systems, Inc.
PR Newswire - Wed Feb 04, 9:46AM CST
Advanced Photonix, Inc.
BAMM: 2.57 (+0.01), API: 0.41 (unch), LUNA: 1.48 (-0.01), ADXS: 7.18 (+0.06), NTCT: 38.98 (+0.57), ADVS: 44.18 (+0.20), CYN: 90.32 (+0.49), ERII: 3.36 (+0.01)
MarketExclusive.com - H.C. Wainwright & Co. Reiterates BUY Rating of Advaxis Inc. and Reports Encouraging Updates on ADXS-HPV Programs
ACCESSWIRE - Wed Feb 04, 9:44AM CST
New York, NY / ACCESSWIRE / February 4, 2015 / Market Exclusive announces that H.C. Wainwright & Co has reported on encouraging updates on Advaxis Inc.'s (Nasdaq:ADXS) ADXS-HPV programs presented at the company's investor day on February 3, 2015. H.C. Wainwright & Co. continues to rate the shares of Advaxis as Buy with a 12-month price target of $14.00 per share.
ADXS: 7.18 (+0.06)
Why Advaxis, Inc. Stock Cratered Today
George Budwell, The Motley Fool - Motley Fool - Tue Feb 03, 1:48PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the developmental-stage cancer...
ADXS: 7.18 (+0.06), MRK: 58.81 (-0.07)
Advaxis, Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing
PR Newswire - Wed Jan 28, 11:51AM CST
Securities lawyers at Dunnam & Dunnam are investigating allegations for Advaxis, Inc. shareholders (NASDAQ: ADXS). Concerned ADXS investors who purchased between January 7, 2015 and January 20, 2015 are encouraged to contact securities attorney Hamilton Lindley by clicking here.
ADXS: 7.18 (+0.06)
Advaxis poised to continue up move
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 8:08AM CST
ADXS: 7.18 (+0.06)
Gynecologic Oncology Group (GOG) Phase 2 Study of Advaxis's Lm-LLO Immunotherapy, ADXS-HPV, for the Treatment of Persistent or Recurrent Cervical Cancer Achieves Safety and Efficacy Criteria
GlobeNewswire - Wed Jan 28, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced an update related to the Phase 2 open-label clinical study of ADXS-HPV (ADXS11-001) in patients with persistent or recurrent cervical cancer with documented disease progression being conducted by the Gynecologic Oncology Group (GOG), now part of NRG Oncology. The study, known as GOG 0265, has completed its first stage and has met the predetermined safety and efficacy criteria required to proceed into the second stage of patient enrollment. This trial is being conducted in the U.S. by the GOG, under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).
ADXS: 7.18 (+0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 11:40AM CST
HEAR: 2.54 (-0.14), NES: 3.52 (+0.13), ADXS: 7.18 (+0.06), ZIOP: 9.64 (-0.35), EXXI: 4.00 (+0.42), JJSF: 100.08 (-0.44), DRAM: 2.39 (-0.04), EPRS: 7.67 (+0.67), CRDS: 2.32 (+0.05), NBG: 1.61 (+0.18), CRRC: 22.96 (+0.22), STRL: 2.99 (unch), NFEC: 2.11 (+0.02), COMM: 30.40 (+0.17), SIMG: 7.25 (-0.01), STAA: 6.76 (-0.02), MSFT: 43.87 (+0.78), PLT: 49.95 (+0.71), SANM: 22.50 (+0.07), IFON: 1.48 (+0.02)
Advaxis Appoints Mayo Pujols Vice President, Manufacturing
GlobeNewswire - Fri Feb 13, 9:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed Mayo Pujols as Vice President, Manufacturing. Mr. Pujols brings to Advaxis more than 22 years of experience in global commercial and clinical manufacturing, technology transfer, and product development strategy.
ADXS: 7.18 (+0.06), MRK: 58.81 (-0.07)
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 12, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), CYAN: 8.72 (+0.13), STMP: 56.92 (-0.24), EPRS: 7.67 (+0.67), EEFT: 53.96 (-0.91), PRQR: 18.32 (-0.86), GTIM: 8.23 (+0.07), DPRX: 12.76 (+0.26), EXPE: 89.49 (-0.08), CVV: 14.68 (-0.26), DGLY: 11.50 (-0.40), DWSN: 6.89 (-0.42)
Advaxis teams up with Incyte in cervical cancer
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 10:47AM CST
ADXS: 7.18 (+0.06), INCY: 75.94 (+0.28)
Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of Two Novel Cancer Immunotherapies for Early Stage Cervical Cancer
GlobeNewswire - Wed Feb 11, 9:55AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with Incyte Corporation (Nasdaq:INCY) to evaluate the combination of Advaxis's Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360). The Phase 2 multicenter, open-label, preoperative window-study will evaluate the safety and efficacy of ADXS-HPV as a monotherapy and in combination with epacadostat in approximately 20 patients with Stage I-IIa human papillomavirus (HPV)-associated cervical cancer.
ADXS: 7.18 (+0.06), INCY: 75.94 (+0.28)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:13AM CST
FCEL: 1.31 (unch), ADXS: 7.18 (+0.06), JONE: 10.18 (+0.18), INXN: 32.04 (+0.14), SDRL: 12.32 (-0.70), NBG: 1.61 (+0.18), GNW: 8.67 (+0.17), WBAI: 17.36 (-0.30), PME: 2.42 (-0.07), RAD: 8.34 (+0.25), BLDP: 2.66 (-0.26), BXE: 2.79 (+0.05), PXD: 157.85 (+9.71), ACHN: 10.89 (-0.20), SDR: 4.66 (+0.10), LGF: 32.17 (+0.08), PIR: 12.52 (+0.17), AOL: 41.78 (+1.22), GNRC: 49.89 (+0.29), GOL: 3.85 (+0.01), DCTH: 1.14 (+0.04), CHS: 18.38 (+0.10)
Biotech Stocks Review - Arena Pharma, Amgen, NPS Pharma, ZIOPHARM Oncology, and Advaxis
PR Newswire - Fri Feb 06, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Amgen Inc. (NASDAQ: AMGN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Advaxis Inc. (NASDAQ: ADXS). Free research report on Arena Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Arena%20P...amp;s=ARNA. On Thursday, February 05, 2015, the NASDAQ Composite ended at 4,765.10, up 1.03%, the Dow Jones Industrial Average advanced 1.20%, to finish the day at 17,884.88, and the S&P 500 closed at 2,062.52, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 813.68, up 1.64%, with the index also advancing 4.56% in the last three months. Register for your complimentary reports at the links given below.
ADXS: 7.18 (+0.06), ZIOP: 9.64 (-0.35), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), ARNA: 4.55 (+0.02)
Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx
at The Street - Fri Feb 06, 5:05AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
BLUE: 90.70 (+0.93), ADXS: 7.18 (+0.06), GILD: 101.90 (+1.10), HEB: 0.25 (+0.01), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), ABBV: 58.05 (+1.00)
Lifshitz & Miller Law Firm Announces Investigation of Advanced Photonix, Inc., Advaxis, Inc., Advent Software, Inc., Books-A-Million, Inc., City National Corporation, Energy Recovery, Inc., and NetScout Systems, Inc.
PR Newswire - Wed Feb 04, 9:46AM CST
Advanced Photonix, Inc.
BAMM: 2.57 (+0.01), API: 0.41 (unch), LUNA: 1.48 (-0.01), ADXS: 7.18 (+0.06), NTCT: 38.98 (+0.57), ADVS: 44.18 (+0.20), CYN: 90.32 (+0.49), ERII: 3.36 (+0.01)
MarketExclusive.com - H.C. Wainwright & Co. Reiterates BUY Rating of Advaxis Inc. and Reports Encouraging Updates on ADXS-HPV Programs
ACCESSWIRE - Wed Feb 04, 9:44AM CST
New York, NY / ACCESSWIRE / February 4, 2015 / Market Exclusive announces that H.C. Wainwright & Co has reported on encouraging updates on Advaxis Inc.'s (Nasdaq:ADXS) ADXS-HPV programs presented at the company's investor day on February 3, 2015. H.C. Wainwright & Co. continues to rate the shares of Advaxis as Buy with a 12-month price target of $14.00 per share.
ADXS: 7.18 (+0.06)
Why Advaxis, Inc. Stock Cratered Today
George Budwell, The Motley Fool - Motley Fool - Tue Feb 03, 1:48PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the developmental-stage cancer...
ADXS: 7.18 (+0.06), MRK: 58.81 (-0.07)
Advaxis, Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into Allegations of Corporate Wrongdoing
PR Newswire - Wed Jan 28, 11:51AM CST
Securities lawyers at Dunnam & Dunnam are investigating allegations for Advaxis, Inc. shareholders (NASDAQ: ADXS). Concerned ADXS investors who purchased between January 7, 2015 and January 20, 2015 are encouraged to contact securities attorney Hamilton Lindley by clicking here.
ADXS: 7.18 (+0.06)
Advaxis poised to continue up move
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 8:08AM CST
ADXS: 7.18 (+0.06)
Gynecologic Oncology Group (GOG) Phase 2 Study of Advaxis's Lm-LLO Immunotherapy, ADXS-HPV, for the Treatment of Persistent or Recurrent Cervical Cancer Achieves Safety and Efficacy Criteria
GlobeNewswire - Wed Jan 28, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced an update related to the Phase 2 open-label clinical study of ADXS-HPV (ADXS11-001) in patients with persistent or recurrent cervical cancer with documented disease progression being conducted by the Gynecologic Oncology Group (GOG), now part of NRG Oncology. The study, known as GOG 0265, has completed its first stage and has met the predetermined safety and efficacy criteria required to proceed into the second stage of patient enrollment. This trial is being conducted in the U.S. by the GOG, under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI).
ADXS: 7.18 (+0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 11:40AM CST
HEAR: 2.54 (-0.14), NES: 3.52 (+0.13), ADXS: 7.18 (+0.06), ZIOP: 9.64 (-0.35), EXXI: 4.00 (+0.42), JJSF: 100.08 (-0.44), DRAM: 2.39 (-0.04), EPRS: 7.67 (+0.67), CRDS: 2.32 (+0.05), NBG: 1.61 (+0.18), CRRC: 22.96 (+0.22), STRL: 2.99 (unch), NFEC: 2.11 (+0.02), COMM: 30.40 (+0.17), SIMG: 7.25 (-0.01), STAA: 6.76 (-0.02), MSFT: 43.87 (+0.78), PLT: 49.95 (+0.71), SANM: 22.50 (+0.07), IFON: 1.48 (+0.02)
